Voyager Therapeutics, Inc.
VYGR
$3.77
-$0.18-4.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.32M | 42.58M | 66.96M | 80.00M | 163.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.32M | 42.58M | 66.96M | 80.00M | 163.78M |
| Cost of Revenue | 131.53M | 125.90M | 126.53M | 122.09M | 115.04M |
| Gross Profit | -100.21M | -83.32M | -59.57M | -42.09M | 48.74M |
| SG&A Expenses | 37.22M | 37.30M | 36.95M | 35.92M | 37.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 168.75M | 163.20M | 163.48M | 158.01M | 152.21M |
| Operating Income | -137.44M | -120.62M | -96.52M | -78.01M | 11.58M |
| Income Before Tax | -126.06M | -107.26M | -84.01M | -64.34M | 26.78M |
| Income Tax Expenses | 719.00K | 679.00K | 688.00K | 665.00K | 903.00K |
| Earnings from Continuing Operations | -126.78 | -107.93 | -84.69 | -65.00 | 25.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -126.78M | -107.93M | -84.69M | -65.00M | 25.88M |
| EBIT | -137.44M | -120.62M | -96.52M | -78.01M | 11.58M |
| EBITDA | -133.41M | -116.40M | -91.97M | -73.28M | 16.63M |
| EPS Basic | -2.17 | -1.85 | -1.46 | -1.13 | 0.75 |
| Normalized Basic EPS | -1.32 | -1.12 | -0.85 | -0.64 | 0.51 |
| EPS Diluted | -2.17 | -1.86 | -1.47 | -1.14 | 0.71 |
| Normalized Diluted EPS | -1.32 | -1.12 | -0.85 | -0.64 | 0.49 |
| Average Basic Shares Outstanding | 233.79M | 232.84M | 231.90M | 230.66M | 216.67M |
| Average Diluted Shares Outstanding | 233.79M | 232.84M | 231.90M | 230.66M | 217.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |